Somatic Genomic Testing for Metastatic or Advanced Cancer

Publication Date: February 17, 2022
Last Updated: March 27, 2023


Provisional Clinical Opinions (PCOs)

Section 1: Multigene Panel-Based Genomic Sequencing with Disease-Specific Approved Markers

PCO 1.1
Genomic testing should be performed for patients with metastatic or advanced solid tumors with adequate performance status in the following two clinical scenarios:
  • When there are genomic biomarker-linked therapies approved by regulatory agencies for their cancer.
  • When considering a treatment for which there are specific genomic biomarker-based contraindications or exclusions.
(, , S )



Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer

Authoring Organization